De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

PTC Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat PTC Therapeutics de winst en omzet met respectievelijk 37.9% en 5.7% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 35.1% per jaar.

Belangrijke informatie

37.9%

Groei van de winst

35.1%

Groei van de winst per aandeel

Biotechs winstgroei	28.6%
Inkomstengroei	5.7%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	01 Oct 2024

Recente toekomstige groei-updates

Recent updates

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Sep 12

Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

Jun 28

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

May 22

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

May 22

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

May 14

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Jun 23

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

May 18

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Mar 02

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Oct 19

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

Aug 05

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

Jul 20

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

Jun 24

Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

May 27

Winst- en omzetgroeiprognoses

NasdaqGS:PTCT - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	824	-204	100	104	12
12/31/2025	695	-355	19	-95	13
12/31/2024	736	-418	-14	-167	14
6/30/2024	900	-480	-230	-115	N/A
3/31/2024	928	-579	-199	-58	N/A
12/31/2023	938	-627	-279	-158	N/A
9/30/2023	798	-642	-343	-224	N/A
6/30/2023	819	-618	-364	-248	N/A
3/31/2023	770	-571	-403	-289	N/A
12/31/2022	699	-559	-509	-357	N/A
9/30/2022	697	-531	-409	-260	N/A
6/30/2022	618	-556	-422	-273	N/A
3/31/2022	569	-522	-395	-249	N/A
12/31/2021	539	-524	-337	-251	N/A
9/30/2021	492	-455	-327	-247	N/A
6/30/2021	472	-391	-250	-169	N/A
3/31/2021	430	-454	-271	-213	N/A
12/31/2020	381	-438	-250	-194	N/A
9/30/2020	358	-441	-193	-140	N/A
6/30/2020	311	-432	-221	-182	N/A
3/31/2020	322	-292	-198	-138	N/A
12/31/2019	307	-252	-144	-99	N/A
9/30/2019	297	-222	-142	-104	N/A
6/30/2019	279	-213	-116	-85	N/A
3/31/2019	262	-181	-72	-54	N/A
12/31/2018	265	-128	-43	-28	N/A
9/30/2018	256	-78	0	9	N/A
6/30/2018	245	-61	-91	-10	N/A
3/31/2018	224	-69	N/A	3	N/A
12/31/2017	194	-79	N/A	-10	N/A
9/30/2017	142	-107	N/A	-45	N/A
6/30/2017	123	-108	N/A	-53	N/A
3/31/2017	90	-130	N/A	-91	N/A
12/31/2016	83	-142	N/A	-104	N/A
9/30/2016	70	-166	N/A	-121	N/A
6/30/2016	57	-174	N/A	-124	N/A
3/31/2016	48	-174	N/A	-129	N/A
12/31/2015	37	-170	N/A	-124	N/A
9/30/2015	37	-147	N/A	-102	N/A
6/30/2015	29	-131	N/A	-91	N/A
3/31/2015	24	-118	N/A	-80	N/A
12/31/2014	25	-94	N/A	-57	N/A
9/30/2014	17	-84	N/A	-64	N/A
6/30/2014	32	-62	N/A	-52	N/A
3/31/2014	37	-51	N/A	-53	N/A
12/31/2013	35	-66	N/A	-47	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat PTCT de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat PTCT de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat PTCT de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van PTCT ( 5.7% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van PTCT ( 5.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PTCT naar verwachting over 3 jaar hoog zal zijn

PTC Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 11%

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024

Consensus EPS estimates fall by 10%

Recent updates

PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients

PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Announces Sepiapterin Nda Submission to Fda

Little Excitement Around PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Revenues

PTC Therapeutics, Inc. Announces Interim PIVOT-HD Results from the Phase 2 PIVOT-HD Study of PTC518 in Huntington's Disease Patients

PTC Therapeutics: Riding The Regulatory Rollercoaster With Translarna

Industry Analysts Just Upgraded Their PTC Therapeutics, Inc. (NASDAQ:PTCT) Revenue Forecasts By 11%

Consensus revenue estimates increase by 11%

New minor risk - Share price stability

PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza

PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts

Consensus revenue estimates increase by 11%

PTC Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

PTC Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Full year 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

PTC Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarn (ataluren) Following Re-examination Procedure

Co-Founder notifies of intention to sell stock

CEO & Director recently sold US$274k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2024

CEO & Director notifies of intention to sell stock

PTC Therapeutics, Inc. Provides Updates on Translarna Regulatory Activities

Consensus EPS estimates fall by 10%

PTC Therapeutics, Inc. Updates Revenue Guidance for Full Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

PTC Therapeutics, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Financial position

Price target decreased by 12% to US$45.64

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

PTC Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

PTC Therapeutics, Inc. Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Ptc Therapeutics Shares Positive Interim Data from Pivot-Hd Clinical Trial in Huntington's Disease Patients

PTC Therapeutics, Inc. Announces Strategic Pipeline Prioritization

Consensus EPS estimates upgraded to US$4.26 loss

PTC Therapeutics, Inc. Announces Cessation of Emily Hill as Chief Financial Officer, Effective on August 20, 2023

Price target increased by 8.6% to US$57.64

PTC Therapeutics, Inc. Announces Aphenity Trial Achieves Primary Endpoint with Sepiapterin in Adult and Pediatric Patients with Phenylketonuria

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO, COO & Director recently sold US$63k worth of stock

Executive VP & Chief Legal Officer notifies of intention to sell stock

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Forecast to breakeven in 2025

Co-Founder recently sold US$120k worth of stock

Chief Operating Officer notifies of intention to sell stock

Co-Founder recently sold US$86k worth of stock

PTC Therapeutics, Inc. Provides Revenue Guidance for the Year 2022 and 2023

PTC Therapeutics, Inc. Announces Resignation of Dawn Svoronos as Member of the Board of Directors

PTC Therapeutics, Inc. Announces That the Brazilian Health Regulatory Agency, Anvisa (Agência Nacional De Vigilância Sanitária), Has Approved Waylivra™ (Volanesorsen) as the First Treatment for Familial Partial Lipodystrophy (Fpl) in Brazil

Medicines and Healthcare Products Regulatory Agency Grants Marketing Authorization for PTC Therapeutics, Inc.'s Upstaza™

Price target decreased to US$51.46

Insufficient new directors

Price target decreased to US$52.31

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

PTC Therapeutics, Inc. announced that it expects to receive $499.999989 million in funding from Blackstone Alternative Credit Advisors LP, Blackstone Life Sciences Advisors L.L.C.

Executive VP & Chief Legal Officer exercised options and sold US$167k worth of stock

PTC Therapeutics, Inc. Provides Update on Ongoing Global PIVOT-HD Trial For PTC518

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.